Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT ID: NCT03486873

This clinical trial, called MK-3475-587, is looking into the long-term safety and effectiveness of a treatment called pembrolizumab (also known as MK-3475) for patients with advanced tumors. If you...

Recruiting

Phase: PHASE3 Conditions: Solid Tumors, Hematologic Malignancies

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT ID: NCT05006716

This clinical trial is studying a new treatment called BGB-16673 for patients with specific types of B-cell cancers, such as Marginal Zone Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leu...

Recruiting

Phase: PHASE1 Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma +7 more

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT ID: NCT05100862

This clinical trial is studying two different treatment combinations for patients with certain types of lymphoma that have returned or not responded to previous treatments. The first combination be...

Recruiting

Phase: PHASE3 Conditions: Marginal Zone Lymphoma, Relapsed/Refractory Follicular Lymphoma

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT ID: NCT05609968

This clinical trial is studying two different treatment options for adults with metastatic non-small cell lung cancer (NSCLC) that has a specific marker called PD-L1, which is found in at least 50%...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

NCT ID: NCT06049212

This clinical trial is examining the safety and effectiveness of a new treatment called sacituzumab tirumotecan, both on its own and in combination with another medication called pembrolizumab. The...

Recruiting

Phase: PHASE1 Conditions: Non-small Cell Lung Cancer, Solid Tumors +3 more

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT ID: NCT06073821

This clinical trial is studying the effectiveness of two different treatment combinations for people with chronic lymphocytic leukemia (CLL), a type of cancer that affects the blood and bone marrow...

Recruiting

Phase: PHASE3 Conditions: CLL

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT ID: NCT06120283

This clinical trial is studying a new medication called BGB-43395, which targets a specific protein involved in cell growth, to see how well it works on its own or in combination with other treatme...

Recruiting

Phase: PHASE1 Conditions: Non-small Cell Lung Cancer, Metastatic Breast Cancer +7 more

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT ID: NCT06615479

This clinical trial, called QUINTESSENTIAL-2, is testing a new treatment called BMS-986393 to see how well it works compared to standard treatments for adults with relapsed or refractory multiple m...

Recruiting

Phase: PHASE3 Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT ID: NCT06760819

This clinical trial is studying a new treatment called BAY2927088, which is designed for people with advanced solid tumors that have specific changes in a gene known as HER2. These tumors can be lo...

Recruiting

Phase: PHASE2 Conditions: Advanced Solid Tumors, HER2 Mutation

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT ID: NCT06846671

This clinical trial is studying a new treatment called BGB-16673 for patients with chronic lymphocytic leukemia (CLL) who have already received certain other treatments. The goal is to see how effe...

Recruiting

Phase: PHASE3 Conditions: Chronic Lymphocytic Leukemia, CLL

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

NCT ID: NCT06882785

This clinical trial is studying a new treatment called KarXT for adults in Japan who are experiencing acute psychosis due to schizophrenia. The main goal is to see how effective and safe KarXT is f...

Recruiting

Phase: PHASE3 Conditions: Schizophrenia

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT ID: NCT05620407

This clinical trial is studying a new medication called deucravacitinib to see how effective and safe it is for people with active systemic lupus erythematosus (SLE), a condition that can cause inf...

Recruiting

Phase: PHASE3 Conditions: Systemic Lupus Erythematosus

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT ID: NCT06140836

The TRIDENT-3 clinical trial is studying two medications, repotrectinib and crizotinib, to see how effective and safe they are for treating patients with a specific type of lung cancer called ROS1-...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT ID: NCT07076121

This clinical trial is studying a new treatment option for people with a type of advanced pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC). Specifically, it’s looking at ...

Not yet recruiting

Phase: PHASE2 Conditions: Pancreatic Ductal Adenocarcinoma

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT ID: NCT06465069

This clinical trial is studying a new drug called LY4052031 to see if it is safe and effective for patients with advanced or metastatic solid tumors, including types of bladder, breast, lung, and p...

Recruiting

Phase: PHASE1 Conditions: Prostate Cancer, Ovarian Cancer +12 more

Pan Tumor Rollover Study

NCT ID: NCT03899155

The Pan Tumor Rollover Study is a clinical trial focused on understanding the long-term safety of a cancer treatment called nivolumab, both on its own and in combination with other therapies. This ...

Recruiting

Phase: PHASE2 Conditions: Cancer

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

NCT ID: NCT04772079

This clinical trial is studying a new medication called Deucravacitinib to see how well it works and how safe it is for children and teenagers aged 4 to under 18 years who have moderate to severe p...

Recruiting

Phase: PHASE3 Conditions: Plaque Psoriasis

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT ID: NCT05020236

The MagnetisMM-5 clinical trial is studying a new treatment option for people with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers want to see if a medication called el...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT ID: NCT05156281

This clinical trial is studying the effectiveness and safety of a new treatment called remibrutinib compared to an existing drug, teriflunomide, in people with relapsing multiple sclerosis (RMS). R...

Recruiting

Phase: PHASE3 Conditions: Relapsing Multiple Sclerosis

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT ID: NCT05458297

This clinical trial is studying a new treatment called zilovertamab vedotin for patients with certain types of B-cell lymphomas, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (...

Recruiting

Phase: PHASE2 Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma +2 more

Main Menu

Clinical Trials in Nagoya, Aichi

110 Active Trials Found in Nagoya

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Pan Tumor Rollover Study

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)